Zacks: Analysts Expect Cardlytics Inc (CDLX) Will Post Earnings of -$0.38 Per Share

Brokerages expect that Cardlytics Inc (NASDAQ:CDLX) will report earnings per share of ($0.38) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cardlytics’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.42). The company is expected to announce its next quarterly earnings results after the market closes on Tuesday, November 13th.

On average, analysts expect that Cardlytics will report full-year earnings of ($1.30) per share for the current fiscal year, with EPS estimates ranging from ($1.36) to ($1.24). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.10) per share, with EPS estimates ranging from ($1.17) to ($0.98). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.32. The firm had revenue of $35.57 million during the quarter, compared to the consensus estimate of $34.89 million. The company’s quarterly revenue was up 8.4% compared to the same quarter last year.

A number of research analysts have recently weighed in on CDLX shares. SunTrust Banks restated a “buy” rating and issued a $27.00 target price on shares of Cardlytics in a report on Tuesday, September 11th. Zacks Investment Research lowered Cardlytics from a “hold” rating to a “sell” rating in a report on Tuesday, August 21st. KeyCorp dropped their target price on Cardlytics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, August 15th. Finally, Bank of America restated a “hold” rating and issued a $22.00 target price on shares of Cardlytics in a report on Friday, August 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.40.

Shares of CDLX stock traded up $0.04 during trading hours on Friday, reaching $19.24. The company had a trading volume of 131,891 shares, compared to its average volume of 168,833. Cardlytics has a 12 month low of $11.10 and a 12 month high of $28.29. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $401.03 million and a PE ratio of -2.40.

In related news, CEO Scott D. Grimes sold 1,445 shares of Cardlytics stock in a transaction on Friday, August 17th. The stock was sold at an average price of $20.66, for a total transaction of $29,853.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Polaris Venture Management Co. sold 150,000 shares of Cardlytics stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $25.04, for a total value of $3,756,000.00. The disclosure for this sale can be found here. Insiders sold 155,194 shares of company stock worth $3,863,308 in the last 90 days.

Institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its holdings in Cardlytics by 72.4% during the third quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock worth $201,000 after acquiring an additional 3,361 shares during the period. California State Teachers Retirement System bought a new stake in Cardlytics during the first quarter worth $122,000. Rockefeller Capital Management L.P. bought a new stake in Cardlytics during the third quarter worth $231,000. Schwab Charles Investment Management Inc. bought a new stake in Cardlytics during the second quarter worth $214,000. Finally, California Public Employees Retirement System bought a new stake in Cardlytics during the first quarter worth $146,000. Institutional investors and hedge funds own 49.82% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply